Insight on Pharmaceuticals and Healthcare in North America

The following industries match your search criteria:

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | » »|

Results are sorted by relevance. Click on heading titles to sort results by different field.

Type Product title / description Pub Price
Report
Report

Prescribing Influences: Alzheimer's Disease - Alleviating symptoms remains the goal for prescribers

This report analyzes the unmet needs of Alzheimer’s disease treatment and the attributes of drugs that influence prescribing decisions. The analysis aims to understand the opportunities in the market and support the positioning of marketed brands.

Published By Datamonitor
13 Jun 2011 $2800
Buy
Report
Report

Pharmaceutical Key Trends 2011: Pharmaceutical Industry Infrastructure Overview

Overview of cost-cutting, M&A and R&D trends across multiple markets including: the US, Japan, France, Germany, Italy, Spain, the UK, Australia, Brazil, Russia, India and China.

Published By Datamonitor
31 Mar 2011 $2800
Buy
Report
Report

Pharmaceutical Key Trends 2011: Healthcare System and Drug Regulatory Overview

Analysis of healthcare expenditure, reforms, pricing and reimbursement and drug regulation across multiple markets including: the US, Japan, France, Germany, Italy, Spain, the UK, Australia, Brazil, Russia, India and China.

Published By Datamonitor
25 Mar 2011 $2800
Buy
Report
Report

Pharmaceutical Key Trends 2011: Biosimilar Market Overview

Comparative analysis of biosimilar drivers and resistors, key players, market access, pricing, and future launches across multiple markets including: the US, Japan, France, Germany, Italy, Spain, the UK, Australia, Brazil, Russia, India and China.

Published By Datamonitor
23 Feb 2011 $2800
Buy
Report
Report

Stakeholder Insight: Major Depressive Disorder - Gaining traction among physicians is crucial in an SSRI-dominated market

Primary research-based analysis of the major depressive disorder market, based on a survey of 180 psychiatrists in the US, Japan, and EU. Includes epidemiology, patient segmentation, treatment trends, perception of key brands, and patient outcomes.

Published By Datamonitor
23 Dec 2010 $6400
Buy
Report
Report

Commercial Insight: Disease Modification in Rheumatoid Arthritis – Market awaits game changing therapies and strategies

Coverage of disease-modifying drugs in the seven major rheumatoid arthritis markets, including indication-specific 10-year forecasts (using both sales and patient-based approaches), detailed brand profiling and an in-depth patient-based case study.

Published By Datamonitor
15 Dec 2010 $6400
Buy
Report
Report

Pipeline and Commercial Insight: Psoriasis - Established brands challenged by new therapies

Overview of the current and future psoriasis market, providing in-depth analysis of recent events in the market together with 10 year indication specific sales forecasts and profiles of key brands and pipeline products across the seven major markets.

Published By Datamonitor
10 Dec 2010 $6400
Buy
Report
Report

Forecast Insight: Depression - High rewards for novel and adjunctive therapies in treatment-resistant depression

Analysis of the current and future market for drugs treating depression. Includes sales forecasts to 2019 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK) of key marketed brands, generics, and pipeline products.

Published By Datamonitor
09 Dec 2010 $6400
Buy
Report
Report

Infectious Diseases Vaccine Market Overview

This report provides an overview of the vaccines industry with detailed profiles of the 5 major vaccine companies. It analyzes trends, sales, R&D and licensing strategies, portfolios and pipelines as well as other individual strengths & weaknesses.

Published By Datamonitor
25 Oct 2010 $6400
Buy
Case Studies
Case Studies

E-Cigarettes: Big Tobacco moves in for the kill, but could profits disappear in a puff of smoke?

The e-cigarette has been growing rapidly in the last two years and product advertising is everywhere, Big Tobacco has moved in rapidly investing heavily, but doubt remains throughout the industry as to just how safe the products really are.

Published By MarketLine
30 Jun 2014 $495
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | » »|

No help is available.